Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNX-102 SL in PTSD
NCT03841773Phase 3Terminated
- Sponsor
- Tonix Pharmaceuticals
- Start
- Mar 2019
- Primary completion
- Apr 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of Tonmya in post-traumatic stress disorder (PTSD), sponsored by Tonix Pharmaceuticals. Started Mar 2019; status: terminated.
02
Drugs
Tonmya
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT03841773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03841773.